Tag: #oncology

NHS launches pilot of rapid genomic test to cut brain tumour diagnosis from weeks to days

NHS England is piloting a rapid genomic test for brain tumours in five specialist centres, aiming to shorten diagnosis from weeks to days.

#nhs, #genomics, #brain-tumour, #diagnostics, #oncology

Durvalumab Plus FLOT Boosts Survival in Resectable Gastric and GEJ Cancer, MATTERHORN Shows

Phase 3 MATTERHORN shows AstraZeneca’s durvalumab added to perioperative FLOT improves overall and event‑free survival in resectable gastric/GEJ cancer.

$AZN, #oncology, #immunotherapy, #durvalumab, #gastric-cancer, #astrazeneca

FDA Approves Rasonque (daraxonrasib), First Targeted Therapy for Most Common Form of Metastatic Pancreatic Cancer

FDA cleared Rasonque for adults with previously treated metastatic pancreatic adenocarcinoma after a Phase 3 trial showed a significant overall survival benefit.

$RVMD, #health, #pancreaticcancer, #oncology, #drugapproval

FDA Grants Accelerated Approval to Replimune’s Tudriqev for PD-1–Resistant Advanced Melanoma

FDA gives accelerated approval to Replimune’s Tudriqev with nivolumab for adults with PD‑1–resistant unresectable advanced melanoma; confirmatory trials required.

$RPLM, #melanoma, #fda, #oncology, #replimune, #drugapproval

FDA Expands IBRANCE Approval for Maintenance Treatment in HR+, HER2+ Metastatic Breast Cancer

FDA expands use of Pfizer’s IBRANCE (palbociclib) as maintenance therapy with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer.

$PFE, #oncology, #breastcancer, #fda, #pharma

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi